Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”)
today announced positive results from a recently-conducted clinical
trial of its bendamustine hydrochloride (“HCl”) product, in which the
dose was delivered in a 50mL admixture in ten minutes (the “rapidly
infused product”) versus a 500mL admixture in the 60-minute infusion
required for Treanda ® (bendamustine HCl).
In this study, Eagle’s rapidly infused product was found to be
bioequivalent to Treanda, which was the primary endpoint of the study.
for - Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture investment picks